PEDF, PPAR-γ, p53: Deadly circuits arise when worlds collide

Cardiovascular Research

Volumn 76, Issue 2, 2007, Pages 195-196

  Gaetano, Carlo ^a   Colussi, Claudia ^a   Capogrossi, Maurizio C ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN P53; SERINE PROTEINASE INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER THERAPY; CELL CYCLE G0 PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; EDITORIAL; HOMEOSTASIS; HUMAN; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL;

APOPTOSIS; ENDOTHELIAL CELLS; EYE PROTEINS; HUMANS; NERVE GROWTH FACTORS; PPAR GAMMA; SERPINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 36649029744     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2007.08.011     Document Type: Editorial

References (13)

1. van Gent D., Sharp P., Morgan K., and Kalsheker N. Serpins: structure, function and molecular evolution. Int J Biochem Cell Biol 35 (2003) 1536-1547
2. Becerra S.P. Structure-function studies on PEDF. A noninhibitory serpin with neurotrophic activity. Adv Exp Med Biol 425 (1997) 223-237
3. Tombran-Tink J., Chader G.G., and Johnson L.V. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 53 (1991) 411-414
4. Tombran-Tink J., and Barnstable C.J. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 4 (2003) 628-636
5. Chen L., Zhang S.S., Barnstable C.J., and Tombran-Tink J. PEDF induces apoptosis in human endothelial cells by activating p38 MAP kinase dependent cleavage of multiple caspases. Biochem Biophys Res Commun 348 (2006) 1288-1295
6. Ho T.C., Chen S.L., Yang Y.C., Liao C.L., Cheng H.C., and Tsao Y.P. PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells. Cardiovasc Res 76 (2007) 213-223
7. Neve B.P., Fruchart J.C., and Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 60 (2000) 1245-1250
8. Li J., and Wang N. Peroxisome proliferator-activated receptor-gamma in vascular biology. Cardiovasc Hematol Disord Drug Targets 7 (2007) 109-117
9. Margeli A., Kouraklis G., and Theocharis S. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis 6 (2003) 165-169
10. Wang T., Xu J., Yu X., Yang R., and Han Z.C. Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 58 (2006) 1-14
11. Mercer J., Mahmoudi M., and Bennett M. DNA damage, p53, apoptosis and vascular disease. Mutat Res 621 (2007) 75-86
12. Bonofiglio D., Aquila S., Catalano S., Gabriele S., Belmonte M., Middea E., et al. Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Mol Endocrinol 20 (2006) 3083-3092
13. Okura T., Nakamura M., Takata Y., Watanabe S., Kitami Y., and Hiwada K. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 407 (2000) 227-235